Tagrisso Improves Overall Survival in EGFR-Mutation Positive NSCLC


Initial treatment with Tagrisso (osimertinib) significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer (NSCLC), according to results of the FLAURA clinical trial presented at the ESMO Congress in Oct 2019. (1,2)

the median overall survival with osimertinib was 38.6 months compared to 31.8 months with first generation EGFR-TKIs.  More than half (54%) of patients in the osimertinib group were alive at three years compared to 44% in the standard care group.

Based on these data, osimertinib should be the preferred front-line therapy for EGFR-mutated lung cancer patients.”

References

  1. LBA5_PR ‘Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis’ will be presented by Suresh S. Ramalingam during the Presidential Symposium I on Saturday, 28 September, 16:30 to 18:20 (CEST) in Barcelona Auditorium (Hall 2). Annals of Oncology, Volume 30, Supplement 5, October 2019
  2. Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that targets both EGFR sensitising and EGFR T790M resistance mutations. It was approved for front-line use by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) after FLAURA met its primary endpoint of progression free survival. The primary results were presented at the ESMO Congress 2017and subsequently published in the New England Journal of Medicine: Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378:113–125. doi:10.1056/NEJMoa1713137.

Copyright © 2019 CancerConsultants. All Rights Reserved.